These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21514150)

  • 61. Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors.
    Tanaka M; Sagawa S; Hoshi J; Shimoma F; Yasue K; Ubukata M; Ikemoto T; Hase Y; Takahashi M; Sasase T; Ueda N; Matsushita M; Inaba T
    Bioorg Med Chem; 2006 Sep; 14(17):5781-94. PubMed ID: 16762554
    [TBL] [Abstract][Full Text] [Related]  

  • 62. (R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
    Tatsumi R; Fujio M; Takanashi S; Numata A; Katayama J; Satoh H; Shiigi Y; Maeda J; Kuriyama M; Horikawa T; Murozono T; Hashimoto K; Tanaka H
    J Med Chem; 2006 Jul; 49(14):4374-83. PubMed ID: 16821797
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
    Qiao JX; King SR; He K; Wong PC; Rendina AR; Luettgen JM; Xin B; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2009 Jan; 19(2):462-8. PubMed ID: 19046881
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
    Fujimoto T; Kunitomo J; Tomata Y; Nishiyama K; Nakashima M; Hirozane M; Yoshikubo S; Hirai K; Marui S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6414-6. PubMed ID: 21917455
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.
    Hattori K; Takamura F; Tanaka A; Takasugi H; Taniguchi K; Nishio M; Koyama S; Seki J; Sakane K
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3284-7. PubMed ID: 15935659
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5.
    Burdi DF; Hunt R; Fan L; Hu T; Wang J; Guo Z; Huang Z; Wu C; Hardy L; Detheux M; Orsini MA; Quinton MS; Lew R; Spear K
    J Med Chem; 2010 Oct; 53(19):7107-18. PubMed ID: 20809633
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
    Hoveyda HR; Marsault E; Gagnon R; Mathieu AP; Vézina M; Landry A; Wang Z; Benakli K; Beaubien S; Saint-Louis C; Brassard M; Pinault JF; Ouellet L; Bhat S; Ramaseshan M; Peng X; Foucher L; Beauchemin S; Bhérer P; Veber DF; Peterson ML; Fraser GL
    J Med Chem; 2011 Dec; 54(24):8305-20. PubMed ID: 22106937
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs.
    Asada M; Obitsu T; Kinoshita A; Nagase T; Yoshida T; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Nakai H; Toda M; Tobe Y
    Bioorg Med Chem; 2010 May; 18(9):3212-23. PubMed ID: 20385498
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
    Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
    J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase.
    Selness SR; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Devraj RV; Messing D; Schindler JF; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4059-65. PubMed ID: 21640588
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.
    Kiesman WF; Zhao J; Conlon PR; Dowling JE; Petter RC; Lutterodt F; Jin X; Smits G; Fure M; Jayaraj A; Kim J; Sullivan G; Linden J
    J Med Chem; 2006 Nov; 49(24):7119-31. PubMed ID: 17125264
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design, synthesis and SAR of a novel series of benzimidazoles as potent NPY Y5 antagonists.
    Pizzi DA; Leslie CP; Mazzali A; Seri C; Biagetti M; Bentley J; Genski T; Di Fabio R; Contini S; Sabbatini FM; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7120-3. PubMed ID: 20951033
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.
    Hong Q; Bakshi RK; Palucki BL; Park MK; Ye Z; He S; Pollard PG; Sebhat IK; Liu J; Guo L; Cashen DE; Martin WJ; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; MacIntyre DE; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2330-4. PubMed ID: 21439820
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
    Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
    Duplantier AJ; Dombroski MA; Subramanyam C; Beaulieu AM; Chang SP; Gabel CA; Jordan C; Kalgutkar AS; Kraus KG; Labasi JM; Mussari C; Perregaux DG; Shepard R; Taylor TJ; Trevena KA; Whitney-Pickett C; Yoon K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3708-11. PubMed ID: 21565499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.